IT·Science Talk

The melanoma vaccine results are exciting, and the caveats matter just as much

As a pharmacist I've been asked about the personalised cancer vaccine three times this week already, so I want to share how I explain it, using the GONOM post's numbers.

The trial was large and serious: more than 1,100 patients at 157 sites, all after surgery for high-risk melanoma. Half got the mRNA vaccine plus Keytruda, half got Keytruda alone. The combination reduced the risk of recurrence or death by 42%. That's a real result.

But: the 58% figure applies only to a subgroup, the patients still cancer-free at six months, and subgroups can flatter a result. The full data are not yet peer-reviewed. Moderna and Merck funded the trial. And similar approaches have failed in bowel and head and neck cancer, so 'it worked in melanoma' does not mean 'it will work in every cancer'.

And it has no approval yet. So my message at the counter is: genuinely hopeful, but not available, and not proven for other cancers.